Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00979238 · ClinicalTrials.gov registry record · Phase 1
Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
A Phase 1 study of Hemophilia B, sponsored by St. Jude Children's Research Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 8
- Study locations
NCT00979238: Active Phase 1 study of Hemophilia B, sponsored by St. Jude Children's Research Hospital.
NCT00979238 is a Phase 1 study of Hemophilia B that is active but no longer recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 14 participants, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (85% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00979238, a Phase 1 study of Hemophilia B, is active but no longer recruiting, sponsored by St. Jude Children's Research Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to determine the safety of giving a normal factor IX gene to treat individuals who have an abnormal or no factor IX gene. Recruitment will be limited to adults (≥ 18 years) with a confirmed diagnosis of hemophilia B (HB), resulting from a missense mutation in the coagulation factor IX (FIX) gene or a nonsense mutation that has not been associated with an inhibitor. Only subjects who have no evidence of active hepatitis or anti-hFIX antibodies, and who have been treated/exposed to Factor IX concentrates for at least ten years and have had an average of 3 bleeding episodes per year requiring FIX administration will be enrolled. Patients will be recruited within the United States for treatment at St. Jude Children's Research Hospital, and patients will be recruited in England and other countries for treatment in London by our British collaborators.
Primary Outcome
Outcome measures are descriptive in nature but data collected in a longitudinal manner will also be analyzed (as and when appropriate) using longitudinal methods such as mixed effect model which takes into account the correlation among the observation taken at various time points within a participant.
Conditions Studied
Interventions
- GENETIC Gene Transfer
- DRUG scAAV2/8-LP1-hFIXco
Study Locations (8)
Texas
- University of Texas Southwestern - Dallas
- Scott and White Memorial Hospital - Temple
California
- Stanford Medical School - Stanford
Kentucky
- University of Kentucky - Lexington
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Hemophilia Center of Western Pennsylvania - Pittsburgh
Tennessee
- St. Jude Children's Research Hospital - Memphis
Other
- Katharine Dormandy Haemophilia Centre and Haemostasis Unit, University College of London - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-02-22 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What the registry record for NCT00979238 still lists
NCT00979238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Hemophilia B appearing as the primary indexed condition, and to 2 interventions - of which Gene Transfer is the first listed.
NCT00979238 lists 8 locations in 7 states (Texas, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT00979238 about?
NCT00979238 is a clinical study titled "Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B". The purpose of this study is to determine the safety of giving a normal factor IX gene to treat individuals who have an abnormal or no factor IX gene. Recruitment will be limited to adults (≥ 18 years) with a confirmed diagnosis of hemophilia B (HB), resulting from a missense mutation in the coagula...
What is the current status of trial NCT00979238?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-02-22. Estimated completion is 2026-03.
What conditions does trial NCT00979238 study?
This clinical trial studies the following conditions: Hemophilia B.
What interventions are being tested in trial NCT00979238?
The interventions under investigation include: Gene Transfer (GENETIC), scAAV2/8-LP1-hFIXco (DRUG).
Who is sponsoring clinical trial NCT00979238?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00979238 being conducted?
This trial has 8 study locations across California, Kentucky, Oregon, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00979238's enrollment target sits among peer trials
14 18th of 20 higher than 3 of 20 other Hemophilia B trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia B trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
-
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RECRUITING · Phase 1
-
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
ACTIVE NOT RECRUITING · Phase 1
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy